Apomorphine protects against MPTP‐induced neurotoxicity in mice

R‐apomorphine is a potent radical scavenger and iron chelator. The neuroprotective property of R‐apomorphine, a dopamine D1‐D2 receptor agonist, has been studied in the MPTP (N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine) model of Parkinson's disease. Pretreatment with 5–10 mg/kg R‐apomorphine administered subcutaneously in C57BL mice protects against MPTP (24 mg/kg administered intraperitoneally) induced loss of nigrostriatal dopamine neurons as indicated by striatal dopamine content, tyrosine hydroxylase content, and tyrosine hydroxylase activity. In vitro, R‐apomorphine inhibited mice striatal MAO‐A and MAO‐B activities with IC50 values of 93 μM and 241 μM. It is suggested that the neuroprotective effect of R‐apomorphine against MPTP neurotoxicity derives from its radical scavenging and MAO inhibitory actions and not from its agonistic activity because the mechanism of MPTP dopaminergic neurotoxicity involves the generation of oxygen radical species‐induced oxidative stress.

[1]  K. Mohanakumar,et al.  Neuroprotection by bromocriptine against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced neurotoxicity in mice1 , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  A J Lees,et al.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[3]  M. Youdim,et al.  Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐Hydroxydopamine , 1998, Movement disorders : official journal of the Movement Disorder Society.

[4]  M. Beal,et al.  S-Methylthiocitrulline, a Neuronal Nitric Oxide Synthase Inhibitor, Protects against Malonate and MPTP Neurotoxicity , 1997, Experimental Neurology.

[5]  J. Cano,et al.  Neuroprotective Effect of the Iron Chelator Desferrioxamine Against MPP+ Toxicity on Striatal Dopaminergic Terminals , 1997, Journal of neurochemistry.

[6]  K. Jellinger,et al.  Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. , 1996, Biochimica et biophysica acta.

[7]  M. Youdim,et al.  Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. , 1996, European journal of pharmacology.

[8]  K. Tipton,et al.  Nature of Inhibition of Mitochondrial Respiratory Complex I by 6‐Hydroxydopamine , 1996, Journal of neurochemistry.

[9]  M. Ebadi,et al.  Oxidative stress and antioxidant therapy in Parkinson's disease , 1996, Progress in Neurobiology.

[10]  J. Nutt,et al.  Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of tolerance , 1995, Movement disorders : official journal of the Movement Disorder Society.

[11]  C. Olanow,et al.  Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra , 1994, Experimental Neurology.

[12]  C. Olanow,et al.  Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study , 1994, Brain Research.

[13]  M. Kohno,et al.  Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro , 1994, Brain Research.

[14]  P. Riederer,et al.  Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.

[15]  Y. Naito,et al.  Antioxidant Properties of Bromocriptine, a Dopamine Agonist , 1994, Journal of neurochemistry.

[16]  N. Hattori,et al.  Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys , 1994, Neuroscience Letters.

[17]  F. Watt,et al.  Increased Iron in the Substantia Nigra Compacta of the MPTP‐Lesioned Hemiparkinsonian African Green Monkey: Evidence from Proton Microprobe Elemental Microanalysis , 1994, Journal of neurochemistry.

[18]  A J Lees,et al.  Dopamine agonists in Parkinson's disease: a look at apomorphine , 1993, Fundamental & clinical pharmacology.

[19]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain , 1992, Brain Research Bulletin.

[20]  D. Ben-shachar,et al.  Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats , 1991, Journal of neurochemistry.

[21]  D. Ben-shachar,et al.  The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.

[22]  C. Winterbourn,et al.  6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. , 1989, Biochemical pharmacology.

[23]  A. Grace,et al.  Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism. , 1989, Molecular and chemical neuropathology.

[24]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence , 1989, Brain Research.

[25]  D. D. Di Monte,et al.  Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1987, Biochemical and biophysical research communications.

[26]  R. Ramsay,et al.  Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.

[27]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[28]  Y. Kobayashi,et al.  RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE DETERMINATIONS IN HUMAN PLASMA. , 1964, Biochemical pharmacology.

[29]  M. Youdim,et al.  Free radical scavengers: chemical concepts and clinical relevance. , 1999, Journal of neural transmission. Supplementum.

[30]  M. Youdim,et al.  Apomorphine is a potent radical scavenger and protects cultured pheochromocytoma cells from 6-OHDA and H2O2-induced cell death. , 1998, Advances in pharmacology.

[31]  M. Youdim,et al.  Mechanism of 6-hydroxydopamine neurotoxicity. , 1997, Journal of neural transmission. Supplementum.

[32]  C. Olanow,et al.  Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders , 1996 .

[33]  S. Gancher.  Pharmacokinetics of apomorphine in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.

[34]  N. Verbeke,et al.  Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implication in their mechanism of action in parkinsonism , 1995, Journal of neural transmission. Parkinson's disease and dementia section.

[35]  P. Riederer,et al.  The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[36]  D. Ben-shachar,et al.  Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. , 1990, Journal of neural transmission. Supplementum.

[37]  G. Niebch,et al.  Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in the rat. , 1990, Journal of neural transmission. Supplementum.